Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Galante

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Prehospital Emergency Care|October 17, 2008
Can emergency medical dispatch systems safely reduce first-responder call volume?David C Cone, Nicholas Galante, Donald S MacMillan
Prehospital Emergency Care|December 16, 2006
Is there a role for first responders in EMS responses to medical facilities?David C Cone, Nicholas Galante, Donald S MacMillan, et al.
IEEE Transactions on Bio-Medical Engineering|April 27, 2011
A novel approach using time-frequency analysis of pulse-oximeter data to detect progressive hypovolemia in spontaneously breathing healthy subjectsNandakumar Selvaraj, Kirk H Shelley, David G Silverman, et al.
Seminars in Arthritis and Rheumatism|June 19, 2017
Development of an imaging mitigation strategy for patient enrolment in the tanezumab nerve growth factor inhibitor (NGF-ab) program with a focus on eligibility assessmentFrank W Roemer, Colin G Miller, Christine R West, et al.
The Lancet. Haematology|March 4, 2024
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trialMichiel Coppens, Steven W Pipe, Wolfgang Miesbach, et al.
Molecular Therapy. Methods & Clinical Development|September 19, 2025
Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 studyRobert Klamroth, Michael Recht, Nigel S Key, et al.
JAMA Neurology|February 15, 2021
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical TrialsMing Lu, Michael J Pontecorvo, Michael D Devous, et al.
Brain : a Journal of Neurology|April 23, 2019
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementiaMichael J Pontecorvo, Michael D Devous, Ian Kennedy, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Prehospital Emergency Care|October 17, 2008
Can emergency medical dispatch systems safely reduce first-responder call volume?David C Cone, Nicholas Galante, Donald S MacMillan
Prehospital Emergency Care|December 16, 2006
Is there a role for first responders in EMS responses to medical facilities?David C Cone, Nicholas Galante, Donald S MacMillan, et al.
IEEE Transactions on Bio-Medical Engineering|April 27, 2011
A novel approach using time-frequency analysis of pulse-oximeter data to detect progressive hypovolemia in spontaneously breathing healthy subjectsNandakumar Selvaraj, Kirk H Shelley, David G Silverman, et al.
Seminars in Arthritis and Rheumatism|June 19, 2017
Development of an imaging mitigation strategy for patient enrolment in the tanezumab nerve growth factor inhibitor (NGF-ab) program with a focus on eligibility assessmentFrank W Roemer, Colin G Miller, Christine R West, et al.
The Lancet. Haematology|March 4, 2024
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trialMichiel Coppens, Steven W Pipe, Wolfgang Miesbach, et al.
Molecular Therapy. Methods & Clinical Development|September 19, 2025
Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 studyRobert Klamroth, Michael Recht, Nigel S Key, et al.
JAMA Neurology|February 15, 2021
Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical TrialsMing Lu, Michael J Pontecorvo, Michael D Devous, et al.
Brain : a Journal of Neurology|April 23, 2019
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementiaMichael J Pontecorvo, Michael D Devous, Ian Kennedy, et al.
Pageof 1